Disease-Free Survival Data from CAPTIVATE Study Demonstrate Benefit of IMBRUVICA ® (ibrutinib)-Based Regimen as Fixed Duration, First-Line Treatment for Patients with Chronic Lymphocytic Leukemia

December 5, 2020 (RARITAN, N.J.) – New data from the Phase 2 CAPTIVATE study were presented today during an oral session at the 2020 American Society of Hematology (ASH) Annual Meeting (Abstract #123). The study evaluated the efficacy and safety of IMBRUVICA® (ibrutinib) plus venetoclax in the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and showed that, after achieving undetectable minimal residual disease (uMRD) in both the blood and bone marrow with the IMBRUVICA® combination regimen, the one-year disease-free survival (DFS) of patients randomized to discontinue active treatment was comparable to that of patients randomized to continue IMBRUVICA® monotherapy (95.3 percent vs. 100 percent, respectively [p=0.1475]).[1] These data, presented by the Janssen Pharmaceutical Companies of Johnson &Johnson, show the synergistic effect of these two therapies and their combined potential to clear disease from peripheral blood (PB) and bone marrow (BM).1 “These data demonstrate the potential of this all-oral, once-daily, chemotherapy-free combination regimen in first-line treatment of CLL,” said William Wierda, M.D., Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center and principal study investigator. “Once-daily treatment with ibrutinib remains the established standard of care in CLL; the latest results from the CAPTIVATE study underscore that the mechan...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news

Related Links:

ConclusionsIn this study, we showed TEW-7197 and ramucirumab considerably decreased invasiveness, thus EMTness in a panel of diffuse-type GC cell lines including GC PDCs. Taken together, we confirmed that combination of TEW-7197 and ramucirumab reduced tumor spheroid and GC PDC-induced blood vessel formation concomitantly in the spheroid-on-a-chip model.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: RESEARCH ARTICLE Source Type: research
Systematically mapping the mechanical properties of skin and tissue is useful for biomechanics research and disease diagnostics. For example, later stage breast cancer and lymphoma manifest themselves as hard nodes under the skin. Currently, mechanical measurements are done manually, with a sense of touch or a handheld tool. Manual measurements do not provide quantitative information and vary depending on the skill of the practitioner. Research shows that tactile sensors could be more sensitive than a hand. We propose a method that uses our previously developed skin-crawling robots to noninvasively test the mechanical prop...
Source: IEEE Transactions on Biomedical Engineering - Category: Biomedical Engineering Source Type: research
Conclusion: The differential characteristics of EDA contributed highly to the accuracy of pain stimulation level detection of the classifiers. The external validity dataset was not considered in the study. Significance: Our approach has the potential for accurate pain quantification using EDA.
Source: IEEE Transactions on Biomedical Engineering - Category: Biomedical Engineering Source Type: research
David J. BierThe Biden administrationis planning to roll out a  new policy in November that denies the right to travel or immigrate to the United States to anyone in the world who is unvaccinated. It will replace various nonsensical travel bans on Europeans, Chinese, Iranians, Brazilians, South Africans, and Indians, but a majority of the world (57 percent) has not received even a  single shot of any of the vaccines, andonly 1.9 percent of people in low ‐​income countries have received at least one dose. This includes pretty much the entire continent of Africa.Currently, everyone —vaccinated or not...
Source: Cato-at-liberty - Category: American Health Authors: Source Type: blogs
This study aimed to determine the relationship between domestic violence against women, adaptation to pregnancy, and maternal-fetal antenatal attachment.Design and MethodsThe study consisted of 385 pregnant women who were referred to the antenatal clinics of a public hospital in eastern Turkey. The data were collected using the Domestic Violence against Women Scale (DVAWS), the Maternal-Fetal Antenatal Attachment Scale (MAAS), and the Prenatal Self-Evaluation Questionnaire (PSEQ) to assess adaptation to pregnancy.FindingsPregnant women were exposed to low level of violence (Mean  ± SD: 64.42  &p...
Source: Perspectives in Psychiatric Care - Category: Psychiatry Authors: Tags: ORIGINAL ARTICLE Source Type: research
New J. Chem., 2021, Accepted Manuscript DOI: 10.1039/D1NJ03533A, PaperLucie Melounkov á, Miriam Syková, Robert Jirásko, Roman Jambor, Radim Havelek, Eva Peterova, Jan Honzicek, Jaromír Vinklárek Two series of heterobimetallic compounds were prepared from the starting complex [cis-L2PtCl2] containing aminophosphine ligand (L = 2,6-iPr2-C6H3-NHPPh2). They cover neutral Pt-Sn complexes [cis-L2PtX(SnCl3)] (X = Cl, SnCl3) and ionic... The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - New J. Chem. latest articles - Category: Chemistry Authors: Source Type: research
Analyst, 2021, Advance Article DOI: 10.1039/D1AN00938A, PaperWei Zhang, Ioannis Karagiannidis, Eliane De Santana Van Vliet, Ruoxin Yao, Ellen J. Beswick, Anhong Zhou Raman spectra acquired from a single living cell were analyzed by a machine learning based algorithm and transformed into aggressiveness score, and further paired with gene expression data for correlation analysis. To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Analyst latest articles - Category: Chemistry Authors: Source Type: research
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVICA® plus venetoclax (I+V) compared to chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of elderly or unfit patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study demonstrated superior progression-free survival (PFS) of a once-daily, all-oral, fixed-duration regimen of I+V versus Clb+O as first-line treatment of CLL; the study also showed improved duration...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A c...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
May 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced new data from the fixed-duration cohort of the investigational Phase 2 CAPTIVATE study, showing that 95 percent of patients treated with combined IMBRUVICA® plus venetoclax were alive and progression-free at two years.[1] Deep remissions were seen across all subgroups, including patients with high-risk chronic lymphocytic leukemia (CLL).1 In addition, long-term data from the RESONATE-2 (PCYC-1115/1116) study will be presented, providing the longest follow-up Phase 3 data for any BTK inhibitor to date. These...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
More News: Acute Leukemia | Allergy & Immunology | Anemia | Arrhythmia | Atrial Fibrillation | Biotechnology | Bleeding | Brain | Cancer | Cancer & Oncology | Cancer Vaccines | Carcinoma | Cardiac Arrhythmia | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Chemotherapy | Child Development | Children | Chronic Leukemia | Chronic Lymphocytic Leukemia | Chronic Pain | Clinical Trials | Education | Environmental Health | Food and Drug Administration (FDA) | Gastroenterology | Genetics | Headache | Health Management | Heart | Hematology | Hormones | Hypertension | Infectious Diseases | Laboratory Medicine | Learning | Legislation | Leukemia | Lymphoma | Macroglobulinemia | Melanoma | Migraine | Neurology | Neuroscience | Neurosurgery | Nonmelanoma Skin Cancer | Oral Cancer | Pain | Pharmaceuticals | Pneomococcal Vaccine | Pneumonia | Pregnancy | Primary CNS Lymphoma | Profits and Losses | Pulmonary Hypertension | Rituxan | Science | Skin | Skin Cancer | Skin Graft | Study | Texas University | Thrombocytopenia | Toxicology | Universities & Medical Training | Vaccines | Veterinary Vaccinations | Waldenstrom's Macroglobulinemia | Warnings | Women